ReviewBiosensors2026
Graphene Quantum Dot-Based Biosensors: Recent Advances in Functionalization Strategies and Biomedical Applications.
Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Graphene Quantum Dots in Neurodegeneration: Protein Aggregation and the Microglial State as Therapeutic Targets.Nanomaterials (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Graphene quantum dots (GQDs) have emerged as a promising class of carbon-based nanomaterials owing to their unique optical properties, tunable surface chemistry, excellent biocompatibility, and high physicochemical stability. These features make GQDs particularly attractive for the development of advanced biosensing platforms. This review provides a comprehensive overview of recent progress in the design, synthesis, and functionalization of GQDs, with a primary focus on their applications in biomedical and biosensors. Various synthesis approaches, including top-down, bottom-up, and chemical methods, are critically discussed in relation to their impact on structural and optical properties. The role of surface engineering and heteroatom doping in modulating sensitivity, selectivity, and signal transduction mechanisms is also highlighted. Furthermore, recent advances in GQD-based biosensors for the detection of clinically relevant biomarkers, environmental analytes, and pathogens are systematically summarized, with emphasis on analytical performance metrics such as sensitivity, selectivity, and limit of detection. In addition, complementary biomedical applications, including bioimaging and therapeutic platforms, are briefly discussed to provide a broader context for the multifunctionality of GQDs. Finally, current challenges and future perspectives toward the rational design of high-performance GQD-based biosensors are outlined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.